Third COVID-19 vaccine dose with BNT162b2 in patients with ANCA-associated vasculitis

Ann Rheum Dis. 2022 Apr;81(4):593-595. doi: 10.1136/annrheumdis-2021-221747. Epub 2022 Jan 10.
No abstract available

Keywords: COVID-19; autoimmune diseases; rituximab; vaccination.

Publication types

  • Letter
  • Observational Study

MeSH terms

  • Adult
  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / immunology*
  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / virology
  • BNT162 Vaccine / administration & dosage*
  • BNT162 Vaccine / immunology
  • COVID-19 / prevention & control*
  • Female
  • Humans
  • Immunity, Humoral / drug effects
  • Immunity, Humoral / immunology
  • Immunogenicity, Vaccine / drug effects
  • Immunogenicity, Vaccine / immunology
  • Immunosuppression Therapy / adverse effects*
  • Male
  • Middle Aged
  • Prospective Studies
  • SARS-CoV-2 / immunology*

Substances

  • BNT162 Vaccine